Bill Brooks, vice president of transportation with Capgemini North America, Inc., lays out the multiple challenges involved in manufacturing, storing and delivering millions of doses of the vaccine for COVID-19 in the coming months.

Bill DeMartino, managing director for the Americas with Riskmethods, discusses how the coronavirus pandemic is impacting risk-management strategies, and whether companies were ready for the disruption that it has caused.

Daniel Hartnett, associate managing director of the Compliance Risk & Diligence Practice of Kroll, advises on the steps that pharmaceutical companies should take to reduce the risk of dealing with third parties, as they develop a COVID-19 vaccine.

A recent dispute between an importer and U.S. Customs and Border Protection (CBP) serves as a stark reminder that the “substantial transformation” test used to determine the country of origin of imported goods is far from straightforward.

Isabelle Glimcher, a fellow at the NYU Stern Center for Business and Human Rights, recommends six steps that government procurement officials should be taking to prevent workers’ rights abuses by suppliers.

The coronavirus pandemic uncovered a serious shortfall in the supply of personal protective equipment (PPE) manufactured within the U.S.

Suresh Acharya, Professor of Practice at the University of Maryland’s Robert H. Smith School of Business, lays out the challenges of creating an end-to-end supply chain that can produce and distribute millions of doses of a vaccine for COVID-19.